{"doi":"10.1002/mds.30003","title":"Effect of <scp>GBA1</scp> Mutations and <scp>APOE</scp> Polymorphisms on Survival and Progression Among Ashkenazi Jews with Dementia with Lewy Bodies","abstract":"BACKGROUND: Glucocerebrosidase 1 (GBA1) mutations are associated with reduced survival in Parkinson's disease but their effect on survival in dementia with Lewy bodies (DLB) is unclear. OBJECTIVE: To assess the impact of GBA1 mutations on survival among Ashkenazi Jews with DLB, while controlling for APOE status. METHODS: One hundred and forty participants from Tel Aviv Medical Center, Israel were genotyped for GBA1 mutations and APOE polymorphisms. Survival rates and follow-up cognitive screening scores were analyzed. RESULTS: GBA1 mutation carriers had a two-fold increased risk of death (HR = 1.999), while APOE status did not independently affect survival. In a subset of patients with available clinical data (N = 63), carriers of the APOE ε4 allele showed faster cognitive deterioration, while GBA1 mutation carriers also declined more rapidly albeit not significantly. CONCLUSION: Understanding the genetic effects on survival and progression is crucial for patient counseling and inclusion in clinical trials.","journal":"Movement Disorders","year":2024,"id":481257,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7976,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":371814,"name":"Gitit Kavé","orcid":"0000-0002-4950-5507","position":1,"is_corresponding":false},{"id":233013,"name":"Anat Mirelman","orcid":"0000-0002-1520-2292","position":2,"is_corresponding":false},{"id":1232064,"name":"Keren Regev","orcid":null,"position":3,"is_corresponding":false},{"id":1290680,"name":"Yoav Piura","orcid":"0000-0003-1004-4560","position":4,"is_corresponding":false},{"id":789891,"name":"Orly Goldstein","orcid":"0000-0001-7781-2734","position":5,"is_corresponding":false},{"id":1321340,"name":"Mali Gana Weisz","orcid":null,"position":6,"is_corresponding":false},{"id":790431,"name":"Anat Bar‐Shira","orcid":null,"position":7,"is_corresponding":false},{"id":1267509,"name":"Tanya Gurevich","orcid":"0000-0003-2092-9848","position":8,"is_corresponding":false},{"id":789896,"name":"Avi Orr‐Urtreger","orcid":"0000-0001-9305-6203","position":9,"is_corresponding":false},{"id":279481,"name":"Roy N. Alcalay","orcid":"0000-0002-5717-4875","position":10,"is_corresponding":false},{"id":388724,"name":"Nir Giladi","orcid":"0000-0003-1482-8522","position":11,"is_corresponding":false},{"id":371813,"name":"Noa Bregman","orcid":"0000-0003-4856-086X","position":12,"is_corresponding":false},{"id":789894,"name":"Tamara Shiner","orcid":"0000-0002-6368-9656","position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":null,"created_at":"2026-07-19T02:07:06.225103Z","pmid":"39212252","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}